Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash & Equivalents (2020 - 2025)

Gain Therapeutics has reported Cash & Equivalents over the past 6 years, most recently at $8.8 million for Q3 2025.

  • Quarterly results put Cash & Equivalents at $8.8 million for Q3 2025, down 26.91% from a year ago — trailing twelve months through Sep 2025 was $8.8 million (down 26.91% YoY), and the annual figure for FY2024 was $10.4 million, down 11.95%.
  • Cash & Equivalents for Q3 2025 was $8.8 million at Gain Therapeutics, up from $6.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for GANX hit a ceiling of $46.6 million in Q1 2021 and a floor of $4.3 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $10.9 million (2022), compared with a mean of $17.8 million.
  • Biggest five-year swings in Cash & Equivalents: surged 392.21% in 2021 and later tumbled 82.56% in 2023.
  • Gain Therapeutics' Cash & Equivalents stood at $36.9 million in 2021, then tumbled by 80.17% to $7.3 million in 2022, then surged by 61.32% to $11.8 million in 2023, then fell by 11.95% to $10.4 million in 2024, then fell by 15.2% to $8.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $8.8 million (Q3 2025), $6.7 million (Q2 2025), and $9.1 million (Q1 2025) per Business Quant data.